Key result
Cryo renal denervation significantly reduced renal tissue norepinephrine concentrations by 81.9% at 28 days compared to untreated kidneys in a normotensive porcine model.
Why the study?
To evaluate the safety and efficacy of a novel cryo renal denervation system in a porcine model.
Does a novel cryo renal denervation system demonstrate safety and efficacy in a porcine model?
Does a novel cryo renal denervation system demonstrate safety and efficacy in a porcine model?
A novel cryo renal denervation system demonstrated procedural safety and effective sympathetic nerve ablation in a preclinical porcine model.
May warrant first-in-human trials of cryo renal denervation; leaves open clinical translation in hypertension.
The objective of this study was to demonstrate the safety and efficacy of a novel cryo renal denervation system (Cryo-RDN) in a porcine model. Procedural and mid-term safety of the Cryo-RDN was demonstrated. Efficacy of the cryoablation was evidenced by histological findings in the renal arteries and reduced renal tissue norepinephrine concentrations on the treated sides. Despite some morphological nerve repair observed between 7 and 28 days, the greater renal norepinephrine suppression in the 28-day animals suggests irreversibly ablated sympathetic nerves.
No takes yet. Share an insight, caveat, or question.
Krackhardt et al. (2025) studied Normotensive (preclinical model for hypertension) (n=8). Cryo Renal Denervation (Cryo-RDN) vs. Untreated contralateral kidney or sham procedure was evaluated on Renal tissue norepinephrine (NE) concentration at 28 days (pooled treated vs untreated) (81.9% reduction, p=<0.001). Cryo renal denervation significantly reduced renal tissue norepinephrine concentrations by 81.9% at 28 days compared to untreated kidneys in a normotensive porcine model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: